These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33054463)

  • 1. Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials.
    Roofeh D; Lescoat A; Khanna D
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):455-466. PubMed ID: 33054463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
    Lescoat A; Varga J; Matucci-Cerinic M; Khanna D
    Expert Opin Investig Drugs; 2021 Jun; 30(6):635-652. PubMed ID: 33909517
    [No Abstract]   [Full Text] [Related]  

  • 3. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies.
    Fallet B; Walker UA
    Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1203-1218. PubMed ID: 33008265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational drugs for the treatment of scleroderma: what's new?
    Colic J; Campochiaro C; Hughes M; Matucci Cerinic M; Dagna L
    Expert Opin Investig Drugs; 2023; 32(7):601-614. PubMed ID: 37526079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs in phase I and phase II clinical trials for systemic sclerosis.
    Chung MP; Chung L
    Expert Opin Investig Drugs; 2020 Apr; 29(4):349-362. PubMed ID: 32178544
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in biological and targeted therapies for systemic sclerosis.
    Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
    Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients.
    Benvenuti F; Zanatta E; Avouac J; Müller-Ladner U; Cozzi F; Hoffmann-Vold AM; Gabrielli A; Distler O; Matucci-Cerinic M; Allanore Y; Doria A
    Expert Rev Clin Immunol; 2020 Nov; 16(11):1065-1074. PubMed ID: 33076716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.
    McMahan ZH; Volkmann ER
    Expert Opin Pharmacother; 2020 Nov; 21(16):2041-2056. PubMed ID: 32674612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
    Distler O; Cozzio A
    Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Costimulatory Pathways in Systemic Sclerosis.
    Boleto G; Allanore Y; Avouac J
    Front Immunol; 2018; 9():2998. PubMed ID: 30619351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging targeted therapies in scleroderma lung and skin fibrosis.
    Maurer B; Distler O
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Trial Design Issues in Systemic Sclerosis: an Update.
    Gordon JK; Domsic RT
    Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs and therapeutics for systemic sclerosis.
    Lee JJ; Pope JE
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis.
    Jordan S; Chung J; Distler O
    Curr Opin Rheumatol; 2013 Nov; 25(6):679-85. PubMed ID: 24047603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.
    Campochiaro C; Allanore Y
    Arthritis Res Ther; 2021 Jun; 23(1):155. PubMed ID: 34074331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis.
    Farina N; Campochiaro C; Lescoat A; Benanti G; De Luca G; Khanna D; Dagna L; Matucci-Cerinic M
    Expert Rev Clin Immunol; 2023; 19(9):1131-1142. PubMed ID: 37366065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.
    White B; Bauer EA; Goldsmith LA; Hochberg MC; Katz LM; Korn JH; Lachenbruch PA; LeRoy EC; Mitrane MP; Paulus HE
    Arthritis Rheum; 1995 Mar; 38(3):351-60. PubMed ID: 7880189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving pharmacotherapy of pulmonary fibrosis.
    Lota HK; Wells AU
    Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.